Stock VERV VERVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Verve Therapeutics, Inc.

Equities

VERV

US92539P1012

Market Closed - Nasdaq
Other stock markets
 21:00:00 09/05/2024 BST 		5-day change 1st Jan Change
6.36 USD +4.61% Intraday chart for Verve Therapeutics, Inc. +3.41% -54.38%
05-07 Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 CI
04-03 Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verve Therapeutics: Q1 Earnings Snapshot
AQ
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
GL
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
GL
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
PR
Verve Therapeutics Announces Updates on its PCSK9 Program
GL
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Verve Therapeutics: Q4 Earnings Snapshot
AQ
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
AQ
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
GL
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
AQ
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
GL
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
GL
Verve Therapeutics, Immersion fall; Tower Semiconductor, Boeing rise, Monday, 11/13/2023
AQ
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
AQ
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERV Stock
  4. News Verve Therapeutics, Inc.
  5. Press Releases